• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survival.

作者信息

Maichl Daniela Simone, Kirner Julius Arthur, Beck Susanne, Cheng Wen-Hui, Krug Melanie, Kuric Martin, Ade Carsten Patrick, Bischler Thorsten, Jakob Franz, Hose Dirk, Seckinger Anja, Ebert Regina, Jundt Franziska

机构信息

Department of Internal Medicine II, University Hospital Würzburg, Oberdürrbacher Straße 6, 97080, Würzburg, Germany.

Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.

出版信息

Blood Cancer J. 2023 Sep 5;13(1):134. doi: 10.1038/s41408-023-00907-6.

DOI:10.1038/s41408-023-00907-6
PMID:37669941
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10480158/
Abstract
摘要

相似文献

1
Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survival.鉴定NOTCH驱动的基质体相关基因作为多发性骨髓瘤患者生存的预后指标。
Blood Cancer J. 2023 Sep 5;13(1):134. doi: 10.1038/s41408-023-00907-6.
2
One-lincRNA and five-mRNA based signature for prognosis of multiple myeloma patients undergoing proteasome inhibitors therapy.基于一个长链非编码 RNA 和五个信使 RNA 的签名，用于预测接受蛋白酶体抑制剂治疗的多发性骨髓瘤患者的预后。
Biomed Pharmacother. 2019 Oct;118:109254. doi: 10.1016/j.biopha.2019.109254. Epub 2019 Jul 26.
3
[Omics Analysis of Ferroptosis and Establishment of Prognostic Model for multiple myeloma Patients].[多发性骨髓瘤患者铁死亡的组学分析及预后模型的建立]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Apr;31(2):411-419. doi: 10.19746/j.cnki.issn.1009-2137.2023.02.015.
4
Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.多发性骨髓瘤的分类与预后评估。一项关于生存及化疗反应与免疫类型、20个单一预后因素、15种临床分期系统及6种形态学分类之间关系的回顾性研究。
Panminerva Med. 1991 Apr-Jun;33(2):93-110.
5
Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1.抗 Notch 治疗通过趋化因子系统 CXCR4/SDF-1 防止多发性骨髓瘤细胞定位于骨髓。
Leukemia. 2013 Jul;27(7):1558-66. doi: 10.1038/leu.2013.27. Epub 2013 Jan 28.
6
Potential prognostic long non-coding RNA identification and their validation in predicting survival of patients with multiple myeloma.多发性骨髓瘤患者潜在预后长链非编码RNA的鉴定及其在预测生存中的验证
Tumour Biol. 2017 Apr;39(4):1010428317694563. doi: 10.1177/1010428317694563.
7
Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche.多发性骨髓瘤衍生的锯齿状配体增加骨髓微环境中的自分泌和旁分泌白细胞介素-6表达。
Oncotarget. 2016 Aug 30;7(35):56013-56029. doi: 10.18632/oncotarget.10820.
8
Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.来那度胺治疗多发性骨髓瘤的预后指标：共识与争议
Expert Rev Anticancer Ther. 2015;15(7):787-804. doi: 10.1586/14737140.2015.1044249. Epub 2015 May 6.
9
[Suppressive effect of Notch signal activation on apoptosis of multiple myeloma cells].[Notch信号激活对多发性骨髓瘤细胞凋亡的抑制作用]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2004 Jun;12(3):335-9.
10
Prognostic indicators for the diagnosis of multiple myeloma.用于多发性骨髓瘤诊断的预后指标。
Oncology (Williston Park). 2004 May;18(5):558-60.

引用本文的文献

1
A comprehensive review of oncogenic Notch signaling in multiple myeloma.多发性骨髓瘤中致癌性Notch信号通路的综合综述。
PeerJ. 2024 Nov 28;12:e18485. doi: 10.7717/peerj.18485. eCollection 2024.

本文引用的文献

1
C1QA, C1QB, and GZMB are novel prognostic biomarkers of skin cutaneous melanoma relating tumor microenvironment.C1QA、C1QB 和 GZMB 是与肿瘤微环境相关的皮肤黑色素瘤的新型预后生物标志物。
Sci Rep. 2022 Nov 28;12(1):20460. doi: 10.1038/s41598-022-24353-9.
2
Upregulation of EMID1 Accelerates to a Favorable Prognosis and Immune Infiltration in Lung Adenocarcinoma.EMID1的上调促进肺腺癌的预后改善和免疫浸润。
J Oncol. 2022 Sep 19;2022:5185202. doi: 10.1155/2022/5185202. eCollection 2022.
3
Heparanase: A Dynamic Promoter of Myeloma Progression.肝素酶：多发性骨髓瘤进展的动态促进剂。
Adv Exp Med Biol. 2020;1221:331-349. doi: 10.1007/978-3-030-34521-1_12.
4
Cancer Cells Exploit Notch Signaling to Redefine a Supportive Cytokine Milieu.癌细胞利用 Notch 信号重新定义支持性细胞因子微环境。
Front Immunol. 2018 Aug 14;9:1823. doi: 10.3389/fimmu.2018.01823. eCollection 2018.
5
CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance.CD38作为轻链淀粉样变性和多发性骨髓瘤的免疫治疗靶点——与分子实体、风险、生存及初始耐药机制的关联
Front Immunol. 2018 Jul 20;9:1676. doi: 10.3389/fimmu.2018.01676. eCollection 2018.
6
The cancer matrisome: From comprehensive characterization to biomarker discovery.癌症基质组学：从全面刻画到生物标志物发现。
Semin Cell Dev Biol. 2019 May;89:157-166. doi: 10.1016/j.semcdb.2018.06.005. Epub 2018 Jul 13.
7
Proteomic characterization of human multiple myeloma bone marrow extracellular matrix.人多发性骨髓瘤骨髓细胞外基质的蛋白质组学特性研究
Leukemia. 2017 Nov;31(11):2426-2434. doi: 10.1038/leu.2017.102. Epub 2017 Mar 27.
8
S100A6 - focus on recent developments.S100A6——关注最新进展。
Biol Chem. 2017 Sep 26;398(10):1087-1094. doi: 10.1515/hsz-2017-0125.
9
Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease.多发性骨髓瘤衍生的基质金属蛋白酶-13介导破骨细胞融合和溶骨性疾病。
J Clin Invest. 2016 May 2;126(5):1759-72. doi: 10.1172/JCI80276. Epub 2016 Apr 4.
10
Myeloma cell-derived Runx2 promotes myeloma progression in bone.骨髓瘤细胞衍生的Runx2促进骨髓瘤在骨中的进展。
Blood. 2015 Jun 4;125(23):3598-608. doi: 10.1182/blood-2014-12-613968. Epub 2015 Apr 10.